leadf
logo-loader
viewMidatech Pharma PLC

Midatech Pharma starts phase 1 trial of hormonal cancer treatment

Following dosing, all subjects will enter a 63-day observation and sampling period.  

Midatech Pharma PLC -

Midatech Pharma PLC (LON:MTPH) has started to dose patients in its phase 1 study of MTD201, a possible new treatment for hormonal-based cancers such as acromegaly and neuroendocrine tumours (NET).  

The first cohort of healthy volunteers, 14 out of 28 subjects, received one dose of Sandostatin 100 microgram/1 ml solution on 5 October, which has been followed by a 30mg injection of MTD201.

The remaining 14 subjects will undergo the same procedures this week to complete the dosing phase of the study.

Following dosing, all subjects will enter a 63-day observation and sampling period.  

Topline results expected by the end of 2019 or early in 2020.

Midatech is developing therapies using three novel delivery mechanisms.

MTD201 uses Q-Sphera, a polymer microsphere innovation used to prolong and control the release of therapeutics over an extended period of time -from weeks to months.

Quick facts: Midatech Pharma PLC

Price: 29 GBX

AIM:MTPH
Market: AIM
Market Cap: £18.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Danakali 're-energised' and focused on getting the Colluli SOP project up...

Danakali Ltd's (ASX:DNK) (OTCMKTS:SBMSF) (LON:DNK) (FRA:SO3) Seamus Cornelius caught up with Proactive's Andrew Scott soon after announcing a restructure of its board. He's confident that their unique Colluli Sulphate of Potash (SOP) Project in Eritrea, Africa, is set to become a global game...

4 hours, 45 minutes ago

2 min read